Memantine decreases hippocampal glutamate levels: A magnetic resonance spectroscopy study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 4, 2008, Pages 1005-1012

  Glodzik, Lidia ^a   King, Kevin G ^a   Gonen, Oded ^a   Liu, Songtao ^a   De Santi, Susan ^a   de Leon, Mony J ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Excitotoxicity; Glutamate; Hippocampus; Magnetic resonance spectroscopy; Memantine

Indexed keywords

GLUTAMIC ACID; MEMANTINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; EXCITOTOXICITY; FEMALE; HIPPOCAMPUS; HUMAN; MALE; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; COGNITION DISORDERS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMANTINE;

EID: 42949125356     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.01.016     Document Type: Article

References (42)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (Fourth Edition) (1994), American Psychiatric Association, Washington, D.C.
2. 1H-MRS at 0.5 T. Neurol 56 (2001) 737-742
3. Bakchine S., and Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimer's Dis (2007) 471-479
4. Bernstein M.A., Fain S.B., and Riederer S.J. Effect of windowing and zero-filled reconstruction of MRI data on spatial resolution and acquisition strategy. J Magn Reson Imaging 14 (2001) 270-280
5. Block W., Jessen F., Traber F., Flacke S., Manka C., Lamerichs R., et al. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol 59 (2002) 828-834
6. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 508 (1987) 333-348
7. Brooker H.R., Mareci T.H., and Mao J.T. Selective Fourier transform localization. Magn Res Med 5 (1987) 417-433
8. Chen J.G., Charles H.C., Barboriak D.P., and Doraiswamy P.M. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand, Suppl 176 (2000) 20-26
9. D'Aniello A., Fisher G., Migliaccio N., Cammisa G., D'Aniello E., and Spinelli P. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients. Neurosci Lett 388 (2005) 49-53
10. Danysz W., and Parsons C.G. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50 (1998) 597-664
11. Dawson R.J., and Wallace D.R. Regulation of phosphate-activated glutaminase (PAG) by glutamate analogues. Neurochem Res 18 (1993) 125-132
12. Du Y.P., Parker D.L., Davis W.L., and Cao G. Reduction of partial-volume artifacts with zero-filled interpolation in three-dimensional MR angiography. J Magn Reson Imaging 4 (1994) 733-741
13. Ernst R.R., Bodenhausen G., and Wokaun A. Principles of nuclear magnetic resonance in one and two dimensions. The international series of monographs on chemistry (1987), Claredon Press, Oxford
14. Folstein M. The mini-mental state examination. In: Crook T., Ferris S.H., and Bartus R. (Eds). Assessment in geriatric psychopharmacology (1983), Mark Powley Associates, New Canaan 47-51
15. Glodzik-Sobanska L., Rusinek H., Mosconi L., Li Y., Zhan J., De Santi S., et al. The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. Neuroimaging Clin N Am 15 (2005) 803-826
16. Goelman G., Liu S., and Gonen O. Reducing voxel bleed in Hadamard-encoded MRI and MRS. Magn Reson Med 55 (2006) 1460-1465
17. Goelman G., Liu S., Hess D., and Gonen O. Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med 56 (2006) 34-40
18. Gonzalez M.I., Susarla B.T.S., Fournier K.M., Sheldon A.L., and Robinson M.B. Constitutive endocytosis and recycling of the neuronal glutamate transporter, excitatory amino acid carrier 1. J Neurochem 103 (2007) 1917-1931
19. Greenamyre J.T., and Porter R.H. Anatomy and physiology of glutamate in the CNS. Neurol 44 (1994) S7-S13
20. Hattori N., Abe K., Sakoda S., and Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. NeuroReport 13 (2002) 183-186
21. Holcomb H.H., Lahti A.C., Medoff D.R., Cullen T., and Tamminga C.A. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 30 (2005) 2275-2282
22. 1H chemical-shift-imaging spectroscopy. J Magn Reson 108 (1995) 213-219
23. Jimenez-Jimenez F.J., Molina J.A., Gomez P., Vargas C., de Bustos F., Benito-Leon J., et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm 105 (1998) 269-277
24. Kornhuber J., Mack-Bukhardt F., and Riederer P. Regional distribution of [H3]MK-801 binding sites in the human brain. Brain Res 489 (1989) 397-399
25. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1 (2004) 101-110
26. Mareci T.H., and Brooker H.R. Essential considerations for spectral localization using indirect gradient encoding of spatial information. J Magn Reson 92 (1991) 229-246
27. Marion D., Ikura M., and Bax A. Improved solvent suppression in one- and two-dimensional NMR spectra by convolution of time domain data. J Magn Reson 84 (1989) 425-430
28. Moran J., Alavez S., Rivera-gaxiola M., Valencia A., and Hurtado S. Effect of NMDA antagonists on the activity of glutaminase and aspartate aminotransferase in the developing rat cerebellum. Int J Dev Neurosci 17 (1999) 57-65
29. 1H NMR spectroscopy. J Magn Reson 104 (1994) 1-10
30. Ottersen O.P. Excitatory aminoacid neurotransmitters: anatomical systems. Excitatory amino acids antagonists (1991) 14-38
31. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurol 53 (1999) 71-79
32. Reisberg B., London E., Ferris S.H., Borenstein J., Scheier L., and de Leon M.J. The brief cognitive rating scale: language, motoric, and mood concomitants in primary degenerative dementia. Psychopharmacol Bull 19 (1983) 702-708
33. Reisberg B., Sclan S.G., Franssen E.H., de Leon M.J., Kluger A., Torossian C.L., et al. Clinical stages of normal aging and Alzheimer's disease: the GDS staging system. Neurosci Res Commun 13 Suppl. 1 (1993) 551-554
34. 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 1031 (2005) 82-89
35. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162 (2005) 394-396
36. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J.L., Norman D., et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurol 49 (1997) 1513-1521
37. Soher B.J., Young K., Govindaraju V., and Maudsley A.A. Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 40 (1998) 822-831
38. Tomiya M., Fukushima T., Kawai J., Aoyama C., Mitsuhashi S., Santa T., et al. Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-d-aspartate receptor antagonist, ketamine. Biomed Chromatogr 20 (2007) 628-633
39. Vermathen P., Laxer K.D., Matson G.B., and Weiner M.W. Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging. Radiology 214 (2000) 403-410
40. Waxman E.A., Baconguis I., Lynch D.R., and Robinson M.B. N-methyl-d-aspartate receptor-dependent regulation of the glutamate transporter excitatory amino acid carrier 1. J Biol Chem 282 (2007) 17594-17607
41. Wenk G.L., Parsons C.G., and Danysz W. Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17 (2006) 411-424
42. Zaaraoui W., Fleysher L., Fleysher R., Liu S., Soher B.J., and Gonen O. Human brain-structure resolved T2 relaxation times of proton metabolites at 3 tesla. Magn Reson Med 57 (2007) 983-989